


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claim 1 (previously presented): A quinazoline derivative of formula I:



wherein:

**each of R<sup>1</sup> and R<sup>2</sup>**, which may be the same or different, is selected from hydrogen, carboxy, cyano, formyl, (1-3C)alkyl, (2-3C)alkanoyl, (1-3C)alkoxycarbonyl, carbamoyl,

N-(1-3C)alkylcarbamoyl and N, N-di-[(1-3C)alkyl]carbamoyl;

**each of R<sup>1a</sup> and R<sup>2a</sup>**, which may be the same or different, is selected from hydrogen and (1-3C)alkyl;

**each of R<sup>3</sup> and R<sup>4</sup>**, which may be the same or different, is selected from (1-3C)alkyl and (2-4C)alkenyl,

wherein any CH or CH<sub>2</sub> or CH<sub>3</sub> within any of R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup> and R<sup>4</sup> optionally bears on each said CH or CH<sub>2</sub> or CH<sub>3</sub> a substituent selected from hydroxy and (1-3C)alkoxy;

**X** is selected from hydrogen, halogeno, (1-4C)alkyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

**each R<sup>5</sup>**, which may be the same or different, is selected from halogeno, hydroxy, (1-4C)alkyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

**Y** is selected from a direct bond, O, S, OC(R<sup>7</sup>)<sub>2</sub>, SC(R<sup>7</sup>)<sub>2</sub>, SO, SO<sub>2</sub>, N(R<sup>7</sup>), CO and N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub> wherein each R<sup>7</sup> is, independently, hydrogen or (1-6C)alkyl;

**Q<sup>1</sup>** is selected from phenyl, pyridyl, pyrazinyl, 1,3-thiazolyl, 1H-imidazolyl, 1H-pyrazolyl, 1,3-oxazolyl and isoxazolyl,

wherein **Q<sup>1</sup>** optionally bears one or more substituents, which may be the same or different, selected from halogeno, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, formyl, mercapto, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, or from a group of the formula: -X<sup>1</sup>-R<sup>8</sup>;

**X<sup>1</sup>** is a direct bond or is selected from O, CO and N(R<sup>9</sup>);

**R<sup>9</sup>** is hydrogen or (1-6C)alkyl;

**R<sup>8</sup>** is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, N-(1-6C)alkylamino-(1-6C)alkyl, N,N-di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, (2-6C)alkanoyl-(1-6C)alkyl or (1-6C)alkoxycarbonyl-(1-6C)alkyl,

wherein any CH<sub>2</sub> or CH<sub>3</sub> within a substituent on **Q<sup>1</sup>** optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkyl]amino;

**R<sup>6</sup>** is selected from hydrogen, (1-6C)alkoxy, (2-6C)alkenyloxy and (2-6C)alkynyloxy,

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents, or a substituent selected from hydroxy and (1-6C)alkoxy;

n is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt thereof.

Claim 2 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein R<sup>1</sup> is selected from hydrogen, methyl and ethyl; R<sup>2</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N,N-di-methylcarbamoyl; and R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 3 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein R<sup>2</sup> is selected from hydrogen, methyl and ethyl; R<sup>1</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N,N-di-methylcarbamoyl; and R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 4 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein R<sup>1</sup> and R<sup>1a</sup> are each hydrogen; R<sup>2</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N,N-di-methylcarbamoyl; and R<sup>2a</sup> is selected from hydrogen and (1-3C)alkyl.

Claim 5 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein R<sup>2</sup> and R<sup>2a</sup> are each hydrogen; R<sup>1</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N,N-di-methylcarbamoyl; and R<sup>1a</sup> is selected from hydrogen and (1-3C)alkyl.

Claim 6 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein R<sup>1</sup> is methyl; and R<sup>2</sup>, R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 7 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein R<sup>2</sup> is methyl; and R<sup>1</sup>, R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 8 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein R<sup>1</sup> and R<sup>1a</sup> are each methyl; and R<sup>2</sup> and R<sup>2a</sup> are each hydrogen.

Claim 9 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein R<sup>2</sup> and R<sup>2a</sup> are each methyl; and R<sup>1</sup> and R<sup>1a</sup> are each hydrogen.

Claim 10 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein each of R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, is selected from (1-3C)alkyl, wherein any CH or CH<sub>2</sub> or CH<sub>3</sub> within any of R<sup>3</sup> and R<sup>4</sup> optionally bears on each said CH or CH<sub>2</sub> or CH<sub>3</sub> one or more substituents selected from hydroxy and (1-3C)alkoxy.

Claim 11 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein each of R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, is selected from methyl, ethyl, propenyl, 2-methoxyethyl and 2-hydroxyethyl.

Claim 12 (previously presented): The quinazoline derivative of formula I as defined in claim 11, wherein each of R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, is selected from methyl, ethyl, propenyl, 2-methoxyethyl and 2-hydroxyethyl.

Claim 13 (previously presented): The quinazoline derivative of formula I as defined in claim 11, wherein R<sup>3</sup> is methyl and R<sup>4</sup> is selected from methyl, ethyl, 2-hydroxyethyl, 2-methoxyethyl and propenyl.

Claim 14 (previously presented): The quinazoline derivative of formula I as defined in claim 10, wherein R<sup>3</sup> and R<sup>4</sup> are each methyl.

Claim 15 (previously presented): The quinazoline derivative of formula I as defined in claim 10, wherein  $R^3$  is ethyl and  $R^4$  is 2-hydroxyethyl.

Claim 16 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein X is selected from hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy.

Claim 17 (previously presented): The quinazoline derivative of formula I as defined in claim 16, wherein X is selected from hydrogen, fluoro, chloro, methyl and methoxy.

Claim 18 (previously presented): The quinazoline derivative of formula I as defined in claim 16, wherein X is selected from methyl and chloro.

Claim 19 (previously presented): The quinazoline derivative of formula I as defined in claim 18, wherein X is chloro.

Claim 20 (previously presented): The quinazoline derivative of formula I as defined in claim 18, wherein X is methyl.

Claim 21 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein Y is selected from O, S and  $OC(R^7)_2$  wherein each  $R^7$  is, independently, hydrogen or (1-4C)alkyl.

Claim 22 (previously presented): The quinazoline derivative of formula I as defined in claim 21, wherein Y is selected from O, S and  $OCH_2$ .

Claim 23 (previously presented): The quinazoline derivative of formula I as defined in claim 21, wherein Y is O.

Claim 24 (previously presented): The quinazoline derivative of formula I as defined in claim 21, wherein Y is S.

Claim 25 (previously presented): The quinazoline derivative of formula I as defined in claim 21, wherein Y is OCH<sub>2</sub>.

Claim 26 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein n is 0.

Claim 27 (previously presented): The quinazoline derivative of formula I as defined in claim 1, wherein Q<sup>1</sup> is selected from phenyl, 2-pyridyl, 2-pyrazinyl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl, 1H-imidazol-2-yl and isoxazol-3-yl, and wherein Q<sup>1</sup> optionally bears one or more substituents, which may be the same or different, as defined in claim 1.

Claim 28 (previously presented): The quinazoline derivative of formula I as defined in claim 27, wherein Q<sup>1</sup> is selected from phenyl, 2-pyridyl, 2-pyrazinyl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl, 1H-imidazol-2-yl and 3-isoxazolyl, and wherein Q<sup>1</sup> optionally bears one or more substituents, which may be the same or different, selected from fluoro and (1-4C)alkyl.

Claim 29 (previously presented): The quinazoline derivative of formula I as defined in claim 27, wherein Q<sup>1</sup> is selected from 3-fluorophenyl, 2-pyridyl, 2-pyrazinyl, 1-methyl-1H-imidazol-2-yl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl and 5-methyl-3-isoxazolyl.

Claim 30 (previously presented): The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>6</sup> is hydrogen.

Claim 31 (previously presented): <sup>A</sup>The quinazoline derivative ~~as defined in claim 1~~ selected from the following:

4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;

Exam. Amdt  
8-12-09  
TNT

4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(1-methyl-1*H*-imidazol-2-ylthio)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(1-methyl-1*H*-imidazol-2-ylthio)anilino)-5-(2-dimethylamino-2-methylethoxy)quinazoline;  
4-(4-(3-Fluorobenzyloxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(4-(3-Fluorobenzyloxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyrazinylmethoxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyrazinylmethoxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzyloxy)anilino)-5-(2-(*N*-ethyl-*N*-methylamino)ethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzyloxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzyloxy)anilino)-5-[2-(*N*-(2-hydroxyethyl)-*N*-methylamino)ethoxy]-quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-(*N*-ethyl-*N*-methylamino)ethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-(*N*-(2-hydroxyethyl)-*N*-methylamino)ethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzyloxy)anilino)-5-(2-dimethylamino-2-methylethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-dimethylamino-2-methylethoxy)quinazoline;  
*N*-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylamino)ethoxy]quinazolin-4-amine;  
*N*-[3-Chloro-4-(pyridin-2-yloxy)phenyl]-5-[2-(dimethylamino)ethoxy]quinazolin-4-amine;  
*N*-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[(1*S*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;  
*N*-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(1*S*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;  
*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine;

*N*-{3-Chloro-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-{3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-*N*-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-*N*-[3-methyl-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-*N*-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-*N*-{3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}quinazolin-4-amine;

5-[2-(Dimethylamino)-2-methylpropoxy]-*N*-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-{3-methoxy-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}quinazolin-4-amine;



5-[2-(Dimethylamino)ethoxy]-*N*-[3-methoxy-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-[3-fluoro-4-(1,3-thiazol-5-ylmethoxy)phenyl]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*S*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[2*S*)-2-(dimethylamino)propyl]oxy}quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[[2*R*)-2-(dimethylamino)propyl]oxy}quinazolin-4-amine;

5-{2-[Allyl(methyl)amino]ethoxy}-*N*-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

2-[2-[(4-{[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}(ethyl)amino]ethanol;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*S*)-2-[(2-methoxyethyl)(methyl)amino]-1-methylethoxy}quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*R*)-2-[ethyl(methyl)amino]-1-methylethoxy}quinazolin-4-amine;

5-[(1*R*)-2-[Allyl(methyl)amino]-1-methylethoxy}-*N*-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*S*)-2-[Allyl(methyl)amino]-1-methylethoxy}-*N*-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

*N*-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[[2*S*)-2-(dimethylamino)propyl]oxy}-quinazolin-4-amine;

*N*-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[[2*R*)-2-(dimethylamino)propyl]oxy}-quinazolin-4-amine;

*N*-{3-Chloro-4-[(1-methyl-1*H*-imidazol-2-yl)thio]phenyl}-5-[[2*S*)-2-(dimethylamino)propyl]oxy}quinazolin-4-amine;


*N*-{3-Chloro-4-[(1-methyl-1*H*-imidazol-2-yl)thio]phenyl}-5-{[(2*R*)-2-(dimethylamino)propyl]oxy}quinazolin-4-amine;  
*N*-{3-Chloro-4-[(1-methyl-1*H*-imidazol-2-yl)thio]phenyl}-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;  
5-[2-(Dimethylamino)-1-methylethoxy]-*N*-(3-methoxy-4-phenoxyphenyl)quinazolin-4-amine;  
5-[2-(Dimethylamino)-1-methylethoxy]-*N*-(3-methoxy-4-phenoxyphenyl)quinazolin-4-amine;  
and  
*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-1,1-dimethylethoxy]quinazolin-4-amine;  
or a pharmaceutically acceptable salt thereof.

Claim 32 (original): A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.


Claims 33-36 (cancelled).

Claim 37 (currently amended): A process for preparing a quinazoline derivative of formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 which comprises:

(a) reacting, optionally in the presence of a suitable base, a quinazoline of formula II:




wherein  $R^5$ ,  $R^6$ ,  $Q^1$ ,  $X$ ,  $Y$  and  $n$  are as defined in claim 1, and wherein ~~except that~~ any functional group is optionally protected and  $L$  is a displaceable group, with an alcohol of formula **III**:



**III**


wherein  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^{2a}$ ,  $R^3$  and  $R^4$  are as defined in claim 1, and wherein ~~except that~~ any functional group is optionally protected; or

- (b) for the preparation of the compounds of formula **I** wherein  $Y$  is  $OC(R^7)_2$ ,  $SC(R^7)_2$  or  $N(R^7)C(R^7)_2$ , reacting, optionally in the presence of a suitable base, a quinazoline of formula **IV**:




**IV**

wherein  $Y$  is O, S or  $N(R^7)$ ; and  $X$ ,  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^{2a}$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$  and  $n$  are as defined in claim 1, and wherein ~~except that~~ any functional group is optionally protected with a compound of formula **V**:




**V**

wherein  $L^1$  is a suitable displaceable group and  $Q^1$  and  $R^7$  are as defined in claim 1, and  
wherein except that any functional group is optionally protected; or  
 (c) reacting a quinazoline of formula VI:




VI

wherein  $L^2$  is a suitable displaceable group and  $Q^1$ ,  $X$ ,  $Y$ ,  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^{2a}$ ,  $R^5$ ,  $R^6$  and  $n$  are as defined in claim 1, and wherein except that any functional group is optionally protected with an amine of formula VII:



VII

wherein  $R^3$  and  $R^4$  are as defined in claim 1, and wherein except that any functional group is optionally protected; or  
 (d) for the preparation of the compounds of the formula I wherein  $R^{2a}$  is hydrogen, the reductive amination in the presence of a suitable reducing agent of the aldehyde or ketone of formula VIII:



VIII


wherein  $Q^1$ , X, Y,  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^5$ ,  $R^6$  and n are as defined in claim 1, and wherein except that any functional group is optionally protected with an amine of the formula VII:



VII


wherein  $R^3$  and  $R^4$  are as defined in claim 1, and wherein except that any functional group is optionally protected; or

- (e) for the preparation of the compounds of the formula I wherein Y is O or  $N(R^7)$  and  $Q^1$  is 2-pyridyl or 4-pyridyl, reacting, in the presence of a suitable catalyst, a quinazoline of the formula IV:




IV

wherein Y is O or  $N(R^7)$ ; and X,  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^{2a}$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and n are as defined in claim 1, and wherein except that any functional group is optionally protected with an amine of formula IVa or of formula IVb:




IVa



IVb

wherein  $L^3$  is a suitable displaceable group; or


- (f) reacting, optionally in the presence of a suitable phosphine and a suitable diazo compound, a quinazoline of the formula II:



II

wherein  $R^5$ ,  $R^6$ ,  $Q^1$ , X, Y and n are as defined in claim 1, and wherein ~~except that~~ any functional group is optionally protected and  $L^4$  is hydroxy, with an alcohol of the formula

III:



III

wherein  $R^1$ ,  $R^{1a}$ ,  $R^2$ ,  $R^{2a}$ ,  $R^3$  and  $R^4$  are as defined in claim 1, and wherein ~~except that~~ any functional group is optionally protected;

and thereafter, optionally:

- (i) ~~converting a quinazoline derivative of the formula I into another quinazoline derivative of the formula I;~~  
 (ii)(i) removing any protecting group that is present;

(iii)(ii) forming a pharmaceutically acceptable salt.

Claim 38 (previously presented): A method for treating a breast tumour in a warm-blooded animal in need of such treatment, which comprises administering to the animal an effective amount of a quinazoline derivative of formula I, or a pharmaceutically-acceptable salt thereof, as defined in claim 1.

Claim 39 (cancelled).